Ozempic has been linked to a rare hearing condition where users report hearing internal sounds such as blood flow or organ noises [1, 2].
This development is significant as GLP-1 agonists have seen widespread adoption for weight loss and diabetes management. A potential link to auditory dysfunction could impact how clinicians monitor patients on these medications and may lead to new warnings for users.
The condition, which has been dubbed “Ozempic ear,” involves patients experiencing echoing noises, or the sound of their own internal bodily functions [1, 2]. While the phenomenon is described as rare, it has surfaced in reports published earlier this week [1].
Researchers suggest the side effect may be related to how GLP-1 agonists interact with the auditory system [1]. The exact biological mechanism that triggers these sounds remains under investigation [1].
Medical professionals are currently examining the relationship between the drug's systemic effects and the auditory nerve. Because the drug alters various metabolic processes, scientists are looking for a specific pathway that could cause a patient to perceive internal sounds that are normally filtered out by the brain [1].
Patients experiencing these symptoms are encouraged to consult their healthcare providers to determine if the medication is the cause. The reports highlight a growing body of evidence regarding the diverse range of side effects associated with the popular class of medication [1, 2].
“Users report hearing internal sounds such as blood flow, organ noises, or echoing noises.”
The emergence of 'Ozempic ear' suggests that GLP-1 agonists may have unexpected interactions with the sensory nervous system. While the condition appears rare, its identification underscores the need for long-term longitudinal studies as these drugs move from specialized diabetes treatment to broad weight-loss applications.
